A man with severe spinal fat compression avoided surgery after tirzepatide-induced weight loss of 60 pounds caused near-complete regression of the fat deposits squeezing his spine.
~60 lbs lostTirzepatide-induced weight loss over one year caused near-complete regression of spinal epidural fat, avoiding the need for surgery
What the researchers found
A 35-year-old man with class II obesity (BMI 37.8) and severe lumbar spinal epidural lipomatosis (SEL) causing progressive neurogenic claudication was treated with tirzepatide instead of surgery. After one year of treatment, he lost approximately 60 pounds, experienced marked symptom resolution, and repeat MRI showed near-complete regression of the epidural fat deposits that had been compressing his spine.
This is the first reported case of pharmacological weight loss reversing SEL, eliminating the need for surgical decompression.
Why it matters
Spinal epidural lipomatosis typically requires surgery when conservative measures fail, carrying risks of complications and recovery time. This case demonstrates that tirzepatide — a dual GIP/GLP-1 peptide receptor agonist — may provide a non-surgical alternative by addressing the root cause (excess fat deposition) rather than just the structural consequence. This expands the known therapeutic potential of incretin-based peptide drugs beyond diabetes and general weight management.
The numbers in context
1 patient · BMI 37.8 kg/m² · ~60 lbs weight loss · 1 year of tirzepatide · Near-complete epidural fat regression on MRI · Surgery avoided
How the study worked
This was a single-patient case report. A 35-year-old man with symptomatic lumbar SEL and class II obesity was treated with tirzepatide after counseling. Clinical outcomes were assessed through symptom evaluation and repeat MRI imaging at approximately one year.
Who was studied
Single 35-year-old male patient with class II obesity and severe lumbar spinal epidural lipomatosis
What this study cannot tell us
This is a single case report — the lowest level of clinical evidence. It cannot establish causation (the weight loss, not tirzepatide specifically, may be the key factor), and results may not generalize to other patients. Long-term durability of the response is unknown, and it is unclear whether weight regain after stopping the medication would lead to SEL recurrence.
How to read the evidence
This is a single case report — the lowest tier of clinical evidence. While the outcome is striking, it represents one patient and cannot establish that tirzepatide is generally effective for this condition. Larger studies are needed.
When this study was published
Published in 2026, this is a very recent case report reflecting the expanding clinical applications of tirzepatide and other incretin peptide drugs in the current medical landscape.
The bigger picture
Tirzepatide and other incretin-based peptide drugs are rapidly expanding beyond their original diabetes indications. This case adds spinal epidural lipomatosis to the growing list of obesity-related conditions that may respond to pharmacological weight loss. As these peptide drugs become more widely prescribed, similar unexpected benefits may emerge across other conditions driven by excess adipose tissue.
Questions still open
- Could GLP-1 or dual GIP/GLP-1 peptide agonists become first-line treatment for obesity-related spinal epidural lipomatosis?
- Would stopping tirzepatide lead to fat reaccumulation and symptom recurrence?
- How many other patients with SEL could avoid surgery with pharmacological weight loss?
Common questions
What is tirzepatide and how does it cause weight loss?
What is spinal epidural lipomatosis?
Read the original research
Resolution of severe lumbar spinal epidural lipomatosis following tirzepatide-induced weight loss: illustrative case.
Journal of neurosurgery. Case lessons, 11(4)
Citation
Tazhibi, Masih; Liu, David D; Chalif, Joshua I; Ali, Rohaid; Chi, John H. (2026). Resolution of severe lumbar spinal epidural lipomatosis following tirzepatide-induced weight loss: illustrative case.. Journal of neurosurgery. Case lessons, 11(4). https://doi.org/10.3171/CASE25886